ArticleNature clinical practice. Rheumatology2009
A new 5-lipoxygenase inhibitor seems to be safe and effective for the treatment of osteoarthritis.
Article in Nature clinical practice. Rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Novel in vitro inhibitory functions of potato tuber proteinaceous inhibitors.Molecular genetics and genomics : MGG · 2015Article
- Structure and ligand based drug design strategies in the development of novel 5- LOX inhibitors.Current medicinal chemistry · 2012Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a clear need for both disease-modifying agents and alternative analgesic therapies in osteoarthritis. Currently, there are none of the former, and the latter are limited by adverse effects, particularly gastrointestinal and cardiovascular effects. A new class of analgesic agent that is under investigation inhibits 5-lipoxygenase (5-LOX), the enzyme that catalyzes the conversion of membrane-bound arachidonic acid to leukotrienes. As leukotrienes are implicated in a wide variety of pathologies, the potential of 5-LOX inhibitors has been explored in conditions as diverse as asthma, acute mountain sickness and coronary artery disease. A new 5-LOX inhibitor, derived from a herb, has undergone a phase II trial in osteoarthritis with promising results. Although a putative mechanism of action suggests a disease-modifying effect, the important outcomes from this trial are good symptom response and a low adverse effect profile, albeit in the small number of patients studied.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.